NCT03108131View on ClinicalTrials.gov

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 7, 2017

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions
Skin Squamous Cell CarcinomaAppendix AdenocarcinomaRare LesionLocally Advanced Malignant NeoplasmLocally Advanced Skin Squamous Cell CarcinomaMetastatic Malignant NeoplasmMetastatic Skin Squamous Cell CarcinomaMetastatic Small Intestinal AdenocarcinomaRare Neoplastic SyndromeRefractory Malignant NeoplasmStage IV Small Intestinal Adenocarcinoma AJCC v8Unresectable Malignant Neoplasm
Interventions
DRUG

Atezolizumab

Given IV

DRUG

Cobimetinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03108131 - Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | Biotech Hunter | Biotech Hunter